NTx Bio's Manufacturing Platform Enables Baylor's Production of Personalized Cancer Vaccine in Diakonos Oncology Phase 1 Trial

NTx Bio announced that its NTxscribe CORE platform is being used by researchers at Baylor College of Medicine to manufacture mRNA for DOC1021 (dubodencel), Diakonos Oncology's personalized double-loaded dendritic cell vaccine, now dosing patients in an industry-sponsored phase 1 trial for refractory melanoma.¹ The company described this as one of the first publicly disclosed clinical translations of its continuous-flow manufacturing platform.¹

How does NTxscribe support DOC1021's manufacturing?

At Baylor, researchers use NTxscribe to amplify tumor mRNA derived from very small surgical biopsies, a foundational step in the double-loaded dendritic cell vaccine platform underlying DOC1021.¹ The mRNA produced by NTxscribe maintains the full-length range of a patient's tumor transcriptome, preserving the integrity of longer sequences so the material carried into the vaccine reflects a full representation of tumor antigens.¹ NTxscribe's role in the Baylor/Diakonos workflow uses the same continuous-flow, hollow fiber bioreactor architecture behind NTx Bio's recently launched NTxscribe FLEX system, which the company said automates a historically hands-on process, supports reproducible output through single-use, fully closed cassettes, simplifies change-over between patient samples, and is designed to shorten translational timelines for early-phase clinical programs.¹

Why does manufacturing consistency matter for personalized cell therapies specifically?

Joan Haab, PhD, chief executive officer of NTx Bio, said, "Manufacturing consistency is one of the biggest hidden challenges in personalized cell and gene therapies, because manufacturing processes for these therapies are largely highly manual. Seeing NTxscribe support a program like DOC1021, from a patient's own tumor DNA all the way to a dosed patient, is exactly the kind of real-world validation we set out to deliver when we built this platform."¹ William Decker, PhD, professor of pathology and immunology at Baylor College of Medicine and inventor of the DOC1021 technology, said, "Working with patient-derived material means we don't get the luxury of a standardized starting point. Automating the mRNA generation step with NTxscribe is solving the most challenging, time intensive, and variable step in the manufacturing process so we can focus our attention on delivering a high-quality product to more patients."¹ Vanaja Konduri, PhD, assistant professor of immunology and inventor of the mRNA amplification procedure, added, "NTxscribe has really improved reproducibility while virtually eliminating batch to batch variability."¹

What does DOC1021 target, and why does refractory melanoma need new options?

DOC1021 is designed to reprogram a patient's own immune cells to mount a targeted response against their tumor, and the phase 1 trial is evaluating the vaccine in patients whose disease no longer responds to standard treatments, including immune checkpoint inhibitors.¹ Roughly 40% to 55% of patients with metastatic melanoma have primary resistance and never respond to anti-PD-1 therapy, while an additional 25% of initial responders later develop secondary resistance and disease progression; treatment options remain limited once patients become refractory to checkpoint inhibitors.² DOC1021 is also in clinical development for glioblastoma and pancreatic ductal adenocarcinoma, two other cancers with substantial unmet treatment need.¹

What happens next?

NTx Bio said NTxscribe FLEX's benchtop platform and scalable output are designed to suit early-phase clinical programs while also supporting the higher-volume manufacturing needs of later development stages.¹ Neither company disclosed a timeline for additional data from the refractory melanoma trial.

References

1. NTx Bio powers Baylor College of Medicine's manufacturing of a personalized cancer vaccine in Diakonos Oncology's Phase 1 refractory melanoma trial. News release. NTx Bio; August 19, 2026. Accessed August 19, 2026.
2. Joshi UM, Hundal J, Mata JR, Schollenberger MD, Warrier G, Luke JJ, Lipson EJ, Funchain P. Beyond checkpoint inhibition: keeping therapeutic options open. Am Soc Clin Oncol Educ Book. 2025. doi:10.1200/EDBK-25-473856